Secondary tabs
Contact details
Miguel-Angel Macia
Main
Edurne Lazaro
Alternate
Publications
Data source publications
- Updated list of Scientific Publications in peer reviewed journals describing the use of BIFAP for pharmacoepidemiology research linked to their respective DOIs.
- Maciá-Martínez M-A, Gil M, Huerta C, et al. Base de Datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP): A data resource for pharmacoepidemiology in Spain. Pharmacoepidemiol Drug Saf. 2020;1–10. https://doi.org/10.1002/pds.5006
Studies
List of studies that have been conducted using the data source
- ADVANCE POC I Risk pillar - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of safety outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children
- ADVANCE POC Study Protocol - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case. Coverage rates of acellular and whole-cell pertussis-containing vaccines in preschool children (ADVANCE Coverage POC)
- Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of pertussis and pertussis related outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children (benefit study on pertussis vaccination)
- Exposure and coverage to routine schedule vaccines in different EU countries (ADVANCE-POC2)
- The risk of acute liver injury associated with the use of antibiotics. A methodological comparison across epidemiological data sources
- NESTED CASE-CONTROL STUDY TO ASSESS THE ASSOCIATION BETWEEN THE USE OF METHYLPHENIDATE AND THE RISK OF VALVULAR HEART DISEASE AND PULMONARY HYPERTENSION
- USE OF DRUGS ACTING ON RENIN-ANGIOTENSIN SYSTEM (RAS) AND RISK OF COVID-19: A CASE-POPULATION STUDY (SRAA-COVID19)
- Real-world effectiveness of different COVID-19 vaccines in Spain: a cohort study based on public electronic health records (BIFAP) (effectiveness of COVID-19 vaccines in Spain)
- Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU
- Metamizole and risk of agranulocytosis
- Risk of thromboembolic events and thrombocytopenia after vaccination against COVID-19 (Thrombosis risk COVID-19 vaccination)
- Establish an EU catalogue of sources of real-world data, characterised by a common set of metadata and data quality measurements
- Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)
- Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: utilization and prescribing trends
- Impact of EU label changes and revised pregnancy prevention programme for medicinal products containing valproate: utilisation and prescribing trends
- Effectiveness of heterologous and booster Covid-19 vaccination in 5 European countries, using a cohort approach in children and adults with a full primary Covid-19 vaccination regimen (Covid Vaccines Effectiveness (CoVE))
- Cohort monitoring of Adverse Events of Special Interest and COVID-19 diagnoses prior to and after COVID-19 vaccination (ECVM)
- Rapid Safety Assessment of SARS-CoV-2 vaccines in EU Member States using electronic health care datasources (CVM Covid19-Vaccine-Monitor-EHR)
- Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines (ACCESS-BGR)
- Effectiveness of antiresorptives in preventing hip fractures in older women (≥ 75 years) with osteoporosis: nested case-control study cohort (BiHip)
- DARWIN EU® - Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023
- DARWIN EU® - Characterising interstitial lung disease in Europe
- SAFETY-VAC: Network of Data Sources for Vaccine Safety Evaluation
- The utilisation of antiepileptics in men and women of childbearing age, and pregnant women in Europe (ADEPT)
- DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications
- SAFETY-VAC: Background incidence estimation of flares of pre-existing chronic diseases using pan-European electronic healthcare data sources. (SAFETY VAC)
- Detection of therapeutic cascades associated with gabapentinoids and benzodiazepines in adults over 65 years old in Spain using BIFAP through prescription sequence symmetry analysis (GABALOOP)
- ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or peri-conceptional ASM exposure through the father
- INCIDENCIA Y PREVALENCIA DE HIPOTIROIDISMO EN ESPAÑA, COMORBILIDAD, TRATAMIENTO Y ASOCIACION CON EFECTOS ADVERSOS DE SALUD (GRACHIPES)
- SAFETY-VAC: Case Definitions for Immunocompromised Populations in Real-World Data Sources.
- DARWIN EU® – Paracetamol prescribing and paracetamol overdose in Europe: a descriptive analysis of trends and patient characteristics
- Asymptomatic hyperuricemia: to treat or not to treat. A target trial emulation to assess major cardiorenal outcomes (HYPER-TTE-HARV)